Bovine lactoferrin decreases histopathological changes in the liver and regulates cytokine production by splenocytes of obstructive jaundiced rats

Inflammation Research

Volumn 52, Issue 7, 2003, Pages 305-310

  Zimecki, M ^a   Dawiskiba, J ^b   Zawirska, B ^b   Krawczyk, Z ^b   Kruzel, M ^c  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Bovine lactoferrin (BLF); IL 6; Liver; Obstructive jaundice (OJ); Rats; TNF

Indexed keywords

INTERLEUKIN 6; LACTOFERRIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE DUCT DILATATION; CELL ACTIVATION; CELL CULTURE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DRUG EFFECT; HISTOPATHOLOGY; KUPFFER CELL; LIVER; LIVER NECROSIS; LYMPHOCYTE; MALE; NECROBIOTIC DISORDER; NONHUMAN; OBSTRUCTIVE JAUNDICE; RANK SUM TEST; RAT; SPLEEN CELL;

EID: 0038574574     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-003-1178-4     Document Type: Article

References (49)

1. Jang WC, Puntis MCA. Immune dysfunction in patients with obstructive jaundice, mediators and implications for treatments. J. HPB Surgery 1997; 10: 129-42.
2. Greig JD, Krukowski ZH Matheson NA. Surgical morbidity and mortality in one hundred and twenty-nine patients with obstructive jaundice. Br J Surg 1988; 75: 216-9.
3. Dawiskiba J, Kornafel P, Kwiatkowskia D, Zimecki M. Alterations of tumor necrosis factor alpha and interleukin 6 production and activity of the reticuloendothelial system in experimental obstructive jaundice in rats. HPB 2002; 4: 11-20.
4. Dawiskiba J, Kwiatkowska D, Zimecki M, Kornafel P, Tyran W, Czapińska E et al. The impairment of wound healing process is correlated with abnormalities of TNF-α production by peritoneal exudate cells in obstructive jaundiced rats. J HPB Surgery 2000; 11: 311-8.
5. Clements WD, Halliday MI, McCaigue MD, Barclay RG, Rowlands BJ. Effects of extrahepatic obstructive jaundice on Kupffer cell clearance capacity. Arch Surg 1993; 128: 200-5.
6. Cameron GR and Prasad LBM. Recovery from biliary obstruction after spontaneous restoration of the obstructed common bile duct. J Pathol Bact 1960; 80: 127-36.
7. Tsai LY, Lee KT, Liu TZ. Evidence for accelerated generation of hydroxyl radicals in experimental obstructive jaundice of rats. Free Radic Biol Med 1998; 24: 732-7.
8. Inan M, Sayek I, Tel BC, Sahin-Erdemli I. Role of endotoxin and nitric oxide in the pathogenesis of renal failure in obstructive jaundice. Br J Surg 1997; 84: 943-7.
9. Quattropani C, Vogt B, Odermatt A, Dick B, Frey BM, Frey FJ. Reduced activity of 11beta-hydroxysteroid dehydrogenase in patients with cholestasis. J Clin Invest 2001; 108: 1299-305.
10. Greve JW, Gouma DJ Soeters BP, Buurman WA. Suppression of cellular immunity in obstructive jaundice caused by endotoxins: a study with germ-free rats. Gastroenterology 1990; 98: 478-85.
11. Deitch EA, Berg R., Specian R. Endotoxin promotes the translocation of bacteria from the gut. Arch Surg 1987; 122: 185-90.
12. Dawiskiba J, Zimecki M, Kwiatkowska D, Kuźmiński A. The effect of endotoxin administration on cytokine production in obstructive jaundiced rats. Arch. Immunol. Ther Exp 2001; 49: 391-7.
13. Saitoh N, Hiraoka T, Uchino R, Miyauchi Y. Endotoxemia and intestinal mucosal dysfunction after the relief of obstructive jaundice by internal and external drainage in rats. Eur Surg Res 1995; 27: 11-8.
14. Hunt DR, Allison ME, Preusice CR, Blumgart LH. Endotoxemia, disturbance of coagulation and obstructive jaundice. Am J Surg 1982; 144: 325-9.
15. Pain JA, Cahill CJ, Gilbert JM, Johnson CD, Trapnell JE, Bailey ME. Prevention of postoperative renal dysfunction in patients with obstructive jaundice: a multicentre study of bile salts and lactulose. Br J Surg 1991; 78: 467-9.
16. Schimpl G, Pesendorfer P, Steinwender G, Feierl G, Ratschek M, Hollwarth ME. Allopurinol reduces bacterial translocation, intestinal mucosal lipid peroxidation, and neutrophil-derived myeloperoxidase activity in chronic portal hypertensive and common bile duct ligated growing rats. Pediatr Res 1996; 40: 422-8.
17. Wang CS, Chan WY, Kloer HU. Comparative studies on the chemical and immunochemical properties of human milk, human pancreatic juice and bovine milk lactoferrin. Comp Biochem Physiol B 1984; 78: 575-80.
18. Baggliolini M, de Duve C, Masson PL, Heremans JF. Association of lactoferrin with specific granules in rabbit heterophil leukocytes. J Exp Med 1970; 131: 559-70.
19. Baveye S, Elass E, Mazurier J, Spik G, Legrand D. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med 1999; 37: 281-6.
20. Lonnerdal B, Iyer S. Lactoferrin: molecular structure and biological function. Annu. Rev. Nutr. 1995; 15: 93-110.
21. Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K, Tomita M. Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta 1992; 1121: 130-6.
22. Teraguchi S, Shin K, Ozawa K, Nakamura S, Fukuwatari Y, Tsuyuki S, et al. Bacteriostatic effect of orally administered bovine lactoferrin on proliferation of Clostridium species in the gut of mice fed bovine milk. Appl Environ Microbiol 1995; 61: 501-6.
23. Wharton BA, Balmer SE, Scott PH. Faecal flora in the newborn. Effect of lactoferrin and related nutrients. Adv Exp Med Biol 1994; 357: 91-8.
24. Kruzel ML, Harari Y, Chen CY, Castro GA. The gut. A key metabolic organ protected by lactoferrin during experimental systemic inflammation in mice. Adv Exp Med Biol 1998; 443: 167-73.
25. Kruzel ML., Harazi Y, Chen C-Y, Castro GA. Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice. Inflammation 2000; 24: 33-44.
26. Kruzel ML, Harari Y, Mailman D, Actor JK, Zimecki M. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin Exp Immunol 2002; 130: 25-31.
27. Mercer DW, Smith GS, Cross JM, Russell DH, Chang L, Cacioppo J. Effects of lipopolysaccharide on intestinal injury; potential role of nitric oxide and lipid peroxidation. J Surg Res 1996; 63: 185-92.
28. Saito K, Nakanuma Y.: Lactoferrin and lysozyme in the intrahepatic bile duct of normal livers and hepatolithiasis. An immunohistochemical study. J Hepatol 1992; 15: 147-53.
29. Elass-Rochard E, Roseanu A, Legrand D, Trif M, Salmon V., Motas C et al. Lactoferrin lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055 B5 lipopolysaccharide Biochem J 1995; 312: 839-45.
30. 2-terminal aminoacid sequence of a T cell-derived lymphokine with growth factor activity for B cell hybridomas. Proc.Natl Acad Soc. USA 1986; 83: 9679-83.
31. Hansen MB, Nielsen SE, Berg K. Reexamination and further development of a precise and rapid dye method for measuring cell growth/kill. J Immunol Meth 1989; 119: 203-10.
32. Espevik T, Nissen-Meyer J. A highly sensitive cell line WEHI 164 clone 13 for measuring cytotoxic factor/rumor necrosis factor from human monocytes. J Immunol Methods 1986; 95: 99-105.
33. Reynolds JV, Murchan P, Redmond HP, Watson PWG, Leonard N, Hill A, et al. Failure of macrophage activation in experimental obstructive jaundice: association with bacterial translocation. Br J Surg 1995; 82: 534-8.
34. Tanaka N, Ryden S, Bergqvist L, Christensen P, Bengmark S. Reticuloendothelial function in rats with obstructive jaundice. Br J Surg 1985; 72: 946-9.
35. Holmberg JT, Bergqvist L, Hagerstrand J, Ihse J, Ryden S. Radio-labelled colloid uptake distribution and pulmonary content and localization of lysosomal enzymes in cholestatic rats. Scand J Gastroenterol 1986; 21: 291-9.
36. Houdijk AP, Boermeester MA, Wesdorp RI, Hack CE, Van Leeuwen PA. Tumor necrosis factor unresponsiveness after surgery in bile duct-ligated rats. Am J Physiol 1996; 271: G980-G6.
37. Drivas G, James O, Wardle N. Study of reticuloendothelial phagocytic capacity in patients with cholestasis. Br Med J 1976; 1: 1568-9.
38. Saba M. Effect of surgical trauma on the clearance and localization of blood-borne particulate matter. Surgery 1972; 71: 675-85.
39. Kimmings AN, van Deventer SJ, Obertop H, Rauws EA, Huibregtse K, Gouma DJ. Endotoxin, cytokines, and endotoxin binding proteins in obstructive jaundice and after preoperative biliary drainage. Gut 2000; 46(5): 725-31.
40. Pain JA. Reticulo-endothelial function in obstructive jaundice. Br J Surg 1987; 74(12): 1091-4.
41. Scott-Conner LE, Grogan JB. The pathophysiology of biliary obstruction and its effect on phagocytic and immune function. J Surg Res 1994; 57: 316-36.
42. Bauman H, Gaudie J. The acute phase response. Immunol. Today 1994; 15: 74-80.
43. Remick DG. Lung and gut injury by rumor necrosis factor. Res Immunol 1993; 144: 326-31.
44. Ellison RT III, Giehl TJ. Killing of gram-negative bacteria by lactoferrin and lysozyme. J. Clin. Invest. 1991; 88: 1080-91.
45. Nobermann L, Dohler JR, Perlick L. Treatment of enterogenic endotoxinemia with lactoferrin in rats. Langenbecks Arch Surg 2001; 386: 146-9.
46. Yamaguchi M, Matsuura M, Kobayashi K, Sasaki H, Yajima T, Kuwata T. Lactoferrin protects against development of hepatitis caused by sensitization of Kupffer cells by lipopolysaccharide. Clin Diagn Lab Immunol 2001; 8: 1234-9.
47. Machnicki M, Zimecki M, Zagulski T. Lactoferrin regulates the release of tumor necrosis factor alpha and interleukin 6 in vivo. Int J Exp Path 1993; 74: 433-9.
48. th World Congress on Trauma, Shock, Inflammation and Sepsis. Munich, February 29-March 4, 2000: 221-5.
49. Houdijk AP, Meijer C, Cuesta MA, Meyer S, Van Leeuwen PAM. Perioperative antiendotoxin strategies. Scand J Gastroent 1997; 32: 93-7.